pone.0262212.s004.docx (6.06 MB)
Study protocol.
journal contribution
posted on 2022-02-04, 18:32 authored by Anshul Agarwal, Aakanksha Khandelwal, Kavita Pal, Naveen Kumar Khare, Vishal Jadhav, Murarilal Gurjar, Sachin Punatar, Anant Gokarn, Avinash Bonda, Lingaraj Nayak, Sadhana Kannan, Vikram Gota, Navin Khattry, Indraneel Mittra(DOCX)
History
Usage metrics
Categories
Keywords
major therapeutic challengeincluded oral mucositisgiven twice dailycommon terminology criteriail &# 8212received vehicle alone1 &# 946xlink "> twentyfree chromatin particlesenchid =& ampclinical trial registry5 &# 956dose level iixlink ">&# 945group 1dose levelreceived resveratrolsalivary tnfprospective dosepreviously reportednovel promultiple myelomamarch 2017mainly dueinflammatory cytokinesinflammation triggeredgroup 2g ).dna damageaugust 2019assess toxicitiesadministering melphalanadministered orally6 mg50 mg40 %)3 groups21 post100 %)039 ).011905
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC